NIH Funds New Tuberculosis Research Advancement Centers

Article

NIH has announced four new grant awards to fund new tuberculosis research advancement centers.

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), announced on April 6, 2022 the funding for the establishment of Tuberculosis Research Advancement Centers (TRACs). The funding will be through four grant awards spanning over five years, with the total funding in the first year alone totaling approximately $4.3 million.

The centers will support the development of the next generation of tuberculosis researchers, providing mentoring, funding support, opportunities for multidisciplinary and collaborative research, and training in laboratory and clinical settings. The continuing improvement of tuberculosis research will allow for the discovery or improvement of diagnostics, therapeutics, and vaccines for the disease.

Tuberculosis is a bacterial disease that is currently the second leading cause of death from a single infectious agent worldwide, after COVID-19. According to NIH, approximately 10 million new tuberculosis cases were diagnosed in 2020 and approximately 1.5 million lives were lost to the disease.

The grant awards were made to Texas Biomedical Research Institute, San Antonio; Johns Hopkins University, Baltimore; Emory University, Atlanta; and University of Washington School of Medicine, Seattle.

Source: NIH

Recent Videos
Preeya Beczek, managing director and co-founder of Beczek.COM, chats about industry trends from 2024 and which of those might impact the industry in 2025, including the big trend of AI.
Kate Coleman, vice president regulatory affairs, quality and compliance, Arriello, chats about industry trends and technological advances.
David Fairen-Jimenez
Industry Outlook 2025: The Rising Prominence of AI in Pharma
Adam Sherlock, CEO of Qinecsa, discusses the changing political landscapes in the US and Europe and how that may affect the bio/pharma industry.
Adam Sherlock, CEO of Qinecsa Solutions
Related Content
© 2025 MJH Life Sciences

All rights reserved.